Beijing E-Town enterprise Evive Biotech announced on May 9 that their independently developed third-generation long-acting granulocyte colony-stimulating factor (G-CSF), Ryzneuta, has been approved for market launch by the China National Medical Products Administration (NMPA). 

As the first domestically approved third-generation long-acting G-CSF, the medicine is used for the prevention and treatment of chemotherapy-induced neutropenia (CIN) in cancer patients.

CIN is a common side effect characterized by a prolonged decrease in neutrophil levels (a type of infection-fighting white blood cell) due to the use of chemotherapy drugs. It increases the risk of infection, fever, and other adverse reactions in cancer patients during the chemotherapy process. 

Ryzneuta is a new type of long-acting G-CSF that stimulates the proliferation and differentiation of neutrophil precursors, thereby enhancing the immune system of those patients. 

It prevents the side effects of neutropenia caused by chemotherapy and avoids reducing or delaying chemotherapy drug dosages, which could impact the effectiveness of tumor treatment.

Ryzneuta has already signed a commercialization cooperation agreement with a subsidiary of Sino Biopharm. The medicine will be marketed nationwide. 

Evive Biotech has signed cooperation agreements with companies such as APOGEPHA, ACROTECH, and KALTEQ to facilitate the entry of Ryzneuta into international markets such as Germany, Switzerland, the United States, Greece, and Cyprus, benefiting more cancer patients worldwide.